Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.8 Announcement

28 Feb 2020 16:57

RNS Number : 5732E
Yesod Bio-Sciences Limited
28 February 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE UK CITY CODE ON TAKEOVERS AND MERGERS

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

FOR IMMEDIATE RELEASE

 

28 February 2020

 

 

Statement by Yesod Bio-Sciences Limited ("Yesod") regarding Redx Pharma Plc ("Redx")

 

Further to the announcement made by Redx on 14 February 2020 in which Redx announced that it was in discussions with a consortium of potential investors (the "Bidder") in relation to a possible cash offer to be made by the Bidder for the entire issued, and to be issued, share capital of Redx and that Redx had consented to an extension of the relevant deadline under Rule 2.6(a) of the UK City Code on Takeovers and Mergers (the "Code"), the Bidder, through its specially incorporated bid vehicle, Yesod, today confirms that it does not intend to make an offer for the entire issued and to be issued share capital of Redx pursuant to Rule 2.7 of the Code.

 

Under Note 2 on Rule 2.8 of the Code, the Bidder and/or Yesod and any person acting in concert with the Bidder and/or Yesod, reserves the right to set aside the restrictions in Rule 2.8 in the following circumstances: (i) with the agreement of the board of Redx; (ii) if a third party announces a firm intention to make an offer for Redx; (iii) if Redx announces a "whitewash" proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); and (iv) if the Panel on Takeovers and Mergers determines there has been a material change of circumstances.

 

Additional Information

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise. Any offer, if made, will be made solely by certain offer documentation which will contain the full terms and conditions of any offer, including details of how it may be accepted.

The distribution of this announcement in jurisdictions other than the United Kingdom and the availability of any offer to shareholders of Redx who are not resident in the United Kingdom may be affected by the laws of relevant jurisdictions. Therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom or shareholders of Redx who are not resident in the United Kingdom will need to inform themselves about, and observe, any applicable requirements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STREAKAPASLEEFA
Date   Source Headline
4th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Feb 20206:27 pmRNSForm 8.3 - RedX Pharma PLC
3rd Feb 202011:45 amRNSForm 8.5 (EPT/RI)
30th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
28th Jan 20207:00 amRNSStatement re Rule 2.6 Extension
24th Jan 202011:05 amRNSHolding(s) in Company
24th Jan 20209:40 amRNSHolding(s) in Company
23rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Jan 20208:32 amRNSForm 8.3 - Redx Pharma plc
22nd Jan 20205:04 pmRNSPaul John Blackmore - Form 8.3 - RedX Pharma
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
22nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
21st Jan 20201:23 pmRNSResult of General Meeting
16th Jan 20209:25 amRNSForm 8.3 - Redx Pharma plc
15th Jan 20204:20 pmRNSForm 8.3 - Redx Pharma PLC
15th Jan 20203:17 pmRNSForm 8.3 - Redx Pharma Plc
15th Jan 20202:57 pmRNSForm 8.3 - Redx Pharma plc
10th Jan 20207:56 amRNSForm 8.3 - Redx Pharma plc
9th Jan 20202:14 pmRNSPublic Opening Position Disclosure
9th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
9th Jan 20207:00 amRNSRXC007 nominated as drug development candidate
7th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
6th Jan 20202:16 pmRNSForm 8.3 - Redx Pharma
6th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Jan 20204:14 pmRNSPosting of Circular to Shareholders
3rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Jan 20202:44 pmRNSForm 8.3 - Redx Pharma plc
2nd Jan 202012:57 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
2nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
31st Dec 20197:00 amRNSLoan Capitalisation, GM Notice and Possible Offer
19th Nov 20197:00 amRNSRedx & Medicines Discovery Catapult awarded grant
7th Nov 20193:30 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSRXC006 poster presentation at ERS Congress
19th Aug 20197:00 amRNSFirst cohort of patients dosed in RXC004 study
18th Jul 201910:24 amEQSHardman & Co Research: RedX Pharma (REDX): Pan-RAF agreement strengthens balance sheet
11th Jul 20191:41 pmEQSHardman & Co Research: Redx Pharma (REDX): Phase I trial resumed
10th Jul 20197:00 amRNSSale of pan-RAF inhibitor programme
10th Jun 20197:01 amRNSInterim Results for six months ended 31 March 2019
10th Jun 20197:00 amRNSShort-term Debt Funding Secured
3rd May 201911:34 amRNSUpdate on Plans to Strengthen Balance Sheet
29th Mar 20197:00 amRNSRedx to present two posters at AACR 2019
28th Feb 20197:00 amRNSIssue of Warrants and Change to Lease Agreement
14th Feb 20197:00 amRNSDirectorate Update
12th Feb 20197:00 amRNSNew in vivo data on ROCK2
6th Feb 201911:25 amRNSReceipt of Outstanding Loan
31st Jan 20197:00 amRNSDeinove return rights to Redx Programme
23rd Jan 201911:25 amRNSResults of Annual General Meeting
21st Jan 20197:00 amRNSRXC004 Trial Approval
10th Jan 20192:05 pmRNSSecond Price Monitoring Extn
10th Jan 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.